In this presentation from the 2016 US Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, held August 26-27 in Alexandria, VA, Dr. Eilliot Winton examines whether there is any real clinical utility in utilizing mutation-based risk stratification approaches in the treatment of patients with myelofibrosis.
Earn accreditation for a related activity at the following location:
http://elc.imedex.com/ELC/Activity-Search.aspx?search=7221
© 2016 Imedex, LLC.
Advertisement Single Between Content
Advertisement Single Between Content
Advertisement Single Between Content
Advertisement Single Below Content
Advertisement Single Below Content
Advertisement Single Below Content